問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberPEP07-102
Active

2023-10-01 - 2026-12-31

Phase I

Recruiting3

ICD-10C45.9

Mesothelioma, unspecified

ICD-10C79.9

Secondary malignant neoplasm of unspecified site

ICD-10C7A.00

Malignant carcinoid tumor of unspecified site

ICD-10C7A.094

Malignant carcinoid tumor of the foregut NOS

ICD-10C7A.095

Malignant carcinoid tumor of the midgut NOS

ICD-10C7A.096

Malignant carcinoid tumor of the hindgut NOS

ICD-10C7A.1

Malignant poorly differentiated neuroendocrine tumors

ICD-10C7A.8

Other malignant neuroendocrine tumors

ICD-10C7B.00

Secondary carcinoid tumors, unspecified site

ICD-10C80.1

Malignant (primary) neoplasm, unspecified

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9199.1

Malignant neoplasm of unspecified site (primary) (secondary)

  • Trial Applicant

    QPS

  • Sponsor

  • Trial scale

    Taiwan Multiple Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator Li-Yuan Bai Division of Hematology & Oncology
China Medical University Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 姜乃榕 Division of Hematology & Oncology
Taipei Veterans General Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chia-Chi Lin Division of Hematology & Oncology
National Taiwan University Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    54 participants

  • Global

    54 participants

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB